Nutex Health (NUTX) Set to Post Quarterly Earnings on Thursday

Nutex Health (NASDAQ:NUTX) will likely be announcing its Q3 2026 results after the market closes on Thursday, November 5th. Analysts expect Nutex Health to announce earnings of $5.54 per share and revenue of $214.82 million for the quarter. Parties are encouraged to explore the company’s upcoming Q3 2026 earnings summary page for the latest details on the call scheduled for Friday, November 6, 2026 at 10:30 AM ET.

Nutex Health (NASDAQ:NUTX) last released its quarterly earnings data on Thursday, August 6th. The company reported $9.38 earnings per share for the quarter, beating the consensus estimate of $4.95 by $4.43. The firm had revenue of $210.75 million during the quarter, compared to the consensus estimate of $215.03 million. Nutex Health had a return on equity of 39.74% and a net margin of 21.25%. On average, analysts expect Nutex Health to post $26.65 EPS for the current fiscal year and $26.76 EPS for the next fiscal year.

Nutex Health Price Performance

NUTX stock traded up $17.36 during midday trading on Wednesday, hitting $196.94. 58,073 shares of the stock were exchanged, compared to its average volume of 166,524. The stock’s 50-day moving average price is $203.08 and its 200-day moving average price is $150.83. The company has a debt-to-equity ratio of 0.59, a quick ratio of 4.96 and a current ratio of 5.00. The stock has a market cap of $1.35 billion, a price-to-earnings ratio of 7.70 and a beta of 0.66. Nutex Health has a fifty-two week low of $83.99 and a fifty-two week high of $226.16.

Wall Street Analysts Forecast Growth

NUTX has been the subject of a number of research analyst reports. Wall Street Zen cut Nutex Health from a “buy” rating to a “hold” rating in a research report on Saturday. Weiss Ratings raised Nutex Health from a “hold (c+)” rating to a “buy (b-)” rating in a research note on Tuesday, October 6th. B. Riley Financial reiterated a “buy” rating on shares of Nutex Health in a research report on Friday, September 4th. Lake Street Capital reissued a “buy” rating and issued a $310.00 price objective (up from $235.00) on shares of Nutex Health in a research note on Tuesday, August 11th. Finally, Zacks Research cut shares of Nutex Health from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, October 6th. Four research analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the stock. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $323.67.

Insider Transactions at Nutex Health

In other Nutex Health news, Director Scott Saunders sold 203 shares of the stock in a transaction on Friday, September 18th. The stock was sold at an average price of $214.25, for a total transaction of $43,492.75. Following the sale, the director owned 400 shares in the company, valued at approximately $85,700. This represents a 33.67% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Insiders own 44.68% of the company’s stock.

About Nutex Health

Nutex Health, Inc (NASDAQ:NUTX) is a physician-led healthcare services company that operates an integrated network of hospitals, medical facilities and physician practices in the United States. The company focuses on providing convenient, community-based care through its micro-hospitals and other healthcare locations.

Its hospital operations generally include emergency services, inpatient care, diagnostic testing and outpatient treatment. Nutex also operates physician networks and supports primary care and specialty providers.